NMN vs NR: What 2026 Head-to-Head Research Shows

The 2026 NMN-versus-NR evidence does not identify a clinical winner. One 65-person randomized, open-label study found comparable whole-blood NAD+ increases after 14 days, while an exploratory six-person crossover reported a larger eight-day increase with NR. The different sample sizes, schedules, analytical endpoints, and study aims explain why a single “better precursor” conclusion would overstate the data.

Research boundary: This article is scientific education, not medical advice. WebberScience materials are for research and laboratory use only, not for human or veterinary use. It provides no dosing, route, administration, treatment, efficacy, safety, or self-experimentation guidance.

What Are NMN, NR, and NAD+?

NAD+ is the cofactor; NMN and NR are precursors

NAD+, or nicotinamide adenine dinucleotide, is a redox cofactor and an enzyme substrate involved in cellular metabolism. NR is nicotinamide riboside, a nucleoside form of vitamin B3. NMN is nicotinamide mononucleotide, a phosphorylated intermediate. They are chemically distinct materials, even though they participate in connected biosynthetic networks.

In the canonical salvage pathway, nicotinamide riboside kinases can convert NR to NMN, and nicotinamide mononucleotide adenylyltransferases can convert NMN to NAD+. Oral handling is more complicated than that two-arrow summary: the 2026 Nature Metabolism paper investigated evidence that gut microbial conversion to nicotinic acid may contribute to the sustained circulatory response.

Why the material identity matters

A study of oral NR does not automatically establish what oral NMN, nicotinamide, nicotinic acid, or NAD+ itself will do. It also does not establish equivalence to a separately sourced laboratory material. Researchers should map every claim to the exact chemical form, formulation, population, schedule, compartment, and assay used in the source.

The 65-Person Nature Metabolism Comparison

Study design and primary endpoint

Christen and colleagues conducted a randomized, open-label, placebo-controlled four-arm study registered as NCT05517122. Sixty-seven healthy adults were randomized; two who received the wrong test product were excluded from the modified intention-to-treat analysis, leaving 65 participants. The analyzed groups received NR at 1 g per day (n=16), NMN at 1 g per day (n=15), nicotinamide at 0.5 g per day (n=17), or placebo (n=17) for 14 days.

The primary endpoint was change in baseline whole-blood NAD+ after 14 days. That wording is important: this was a biomarker study in generally young, healthy adults, not a trial of lifespan, cognition, mobility, metabolic disease, or clinical benefit.

What the trial found

Compared with placebo, baseline whole-blood NAD+ increased by about twofold in both the NR and NMN groups. The reported adjusted concentration differences were 49.4 µM for NR and 43.1 µM for NMN, and the authors concluded that the two precursors comparably increased circulatory NAD+ under this design. Nicotinamide did not produce a significant chronic increase.

The nicotinamide arm did produce a strong acute homocysteine signal: the median incremental area under the curve rose more than eightfold relative to placebo on the measured days. This is a short-term biomarker observation. It should not be rewritten as a diagnosed event, a universal risk estimate, or evidence about lower amounts outside this protocol.

The microbiome hypothesis

Alongside the clinical measurements, the researchers used ex vivo fermentation with human-derived microbiota. Their data supported a model in which NR and NMN can give rise to nicotinic acid and engage the Preiss–Handler pathway. Because part of that work occurred outside the body in controlled fermentation systems, it is mechanism-generating evidence. It does not prove that a microbiome change improves health.

The Six-Person Berven Crossover Study

An intensive pharmacokinetic design

Berven and colleagues published a phase I pharmacokinetic study in iScience. Stage 1 used a randomized, open-label crossover in six healthy adults—three women and three men, ages 43 to 47. Participants received 600 mg twice daily of NR or NMN for eight days, followed by washout and crossover. Whole-blood total NAD was measured with LC-MS/MS, while cerebral NAD was estimated with phosphorus-31 magnetic resonance spectroscopy.

NR increased mean whole-blood NAD from 27.3 to 70.51 µM by day 8. NMN increased it from 31.79 to 53.67 µM by day 8 and peaked on day 9. The authors reported that NR produced an approximately 2.3-fold larger increase through day 8. They also reported that this difference remained significant after adjusting for molecular weight and aligning the comparison to each precursor’s peak time.

What the brain measurements did—and did not—show

Neither NR nor NMN produced a significant group-level cerebral NAD increase during the eight-day head-to-head stage, and the brain measurements did not significantly differ between the two precursors. That means this stage does not demonstrate that one precursor enters or affects the brain better than the other.

Stage 2 then tested NR only for four weeks in six healthy adults and six people with Parkinson’s disease. In pooled analysis, mean brain NAD rose to 134.55% of baseline after four weeks. The healthy subgroup showed an increase over time in the longitudinal model, while its baseline-to-week-four paired comparison narrowly missed conventional significance; the Parkinson’s subgroup had a significant paired comparison. Because NMN was not included in stage 2, the four-week result cannot support a four-week NMN-versus-NR claim. It also measured NAD, not cognition or disease modification.

Why the Two 2026 Results Are Different

Feature	Christen et al.	Berven et al.
Publication	Nature Metabolism, January 2026	iScience, January 2026 online / March issue
Design	Randomized, open-label, placebo-controlled, parallel groups	Phase I, randomized open-label crossover plus a separate NR-only stage
Head-to-head sample	31 analyzed across NR and NMN arms; 65 total across four arms	6 healthy adults
Head-to-head duration	14 days	8 days
Mass amount	1 g/day of NR or NMN	1.2 g/day of NR or NMN
Blood conclusion	Comparable chronic whole-blood NAD+ increases	About 2.3-fold larger total blood NAD increase with NR
Brain comparison	Not measured	No significant NR-versus-NMN difference at 8 days
Clinical outcomes	Not established	Not established

The studies did not reproduce the same experiment. They used different participant numbers, schedules, mass amounts, statistical models, and NAD measures. The crossover was efficient for controlling between-person variation but too small to provide a stable population estimate. The larger study had parallel groups and placebo control but remained open label and short.

Equal mass is also not equal molar exposure. Berven’s paper identified NR chloride at 290.70 g/mol and NMN at 334.22 g/mol, yielding roughly 15% more NR molecules at the same mass. Its adjusted analysis still found a difference, but that does not erase the broader design and sample-size limitations.

Evidence Quality and Conflict Disclosures

Question	What the evidence supports	What remains unsupported
Can both raise a blood NAD biomarker?	Yes, under the short oral protocols studied in healthy adults.	A universal response in every population or formulation.
Is NR definitively superior?	One six-person crossover reported a larger blood response.	A replicated clinical advantage or better health outcome.
Does either improve brain function?	Four weeks of NR changed a pooled brain NAD biomarker.	Better cognition, neuroprotection, or disease treatment.
Does the microbiome participate?	The larger paper supports a gut-dependent mechanistic model.	A demonstrated microbiome-mediated clinical benefit.

Conflicts do not invalidate a study, but they belong in evidence appraisal. The Nature Metabolism paper disclosed that most authors worked for Nestlé Research or Nestlé Health Science. The Berven paper disclosed that two authors were inventors on patent applications involving NR for Parkinson’s disease and related disorders. Independent replication would strengthen confidence in both findings.

What the Research Still Cannot Answer

• Whether either precursor improves a meaningful health or functional outcome in a direct head-to-head trial.
• Whether the blood difference from the six-person crossover replicates in a larger, blinded study.
• How results change with matched molar exposure, formulation, age, baseline NAD status, diet, microbiome composition, or disease state.
• Whether changes in whole blood reflect the same changes in muscle, liver, brain, or another tissue.
• Whether long-term exposure preserves the short-term biomarker patterns or introduces different effects.
• Whether a measured NAD increase is beneficial, neutral, or context-dependent for a particular research question.

For broader background, use WebberScience’s NAD+ research guide and longevity research guide. The 5-Amino-1MQ and NNMT evidence review covers a separate NAD-adjacent mechanism and should not be treated as NMN or NR evidence.

Key Terms and Definitions

NAD+

The oxidized form of nicotinamide adenine dinucleotide, a metabolic cofactor and enzyme substrate.

NMN

Nicotinamide mononucleotide, an intermediate that NMNAT enzymes can convert to NAD+.

NR

Nicotinamide riboside, a nucleoside precursor that can be converted to NMN.

Nicotinamide or Nam

A vitamin B3 form distinct from NR and NMN.

Pharmacokinetics

The time course of a material or measured biochemical response during and after exposure.

31P-MRS

Phosphorus-31 magnetic resonance spectroscopy, a non-invasive method used here to estimate cerebral NAD.

Biomarker

A measurable biological signal; a biomarker change is not automatically a clinical benefit.

Frequently Asked Questions About NMN vs NR

What is the difference between NMN and NR?

Nicotinamide mononucleotide and nicotinamide riboside are different NAD+ precursors. NR can be phosphorylated to NMN, and NMN can then be converted to NAD+; oral metabolism may also involve the gut microbiome and nicotinic-acid pathways.

Which raised whole-blood NAD+ more in the 2026 studies?

The 65-person Nature Metabolism study found comparable increases after 14 days. A separate six-person crossover study reported an approximately 2.3-fold larger increase with NR over eight days. Different designs and small samples prevent a clinical winner claim.

Did the 2026 studies prove that NMN or NR improves health?

No. Their main measurements were NAD-related biomarkers and pharmacokinetics. They did not establish slower aging, better cognition, disease treatment, or another clinical benefit.

How large was the Nature Metabolism study?

Sixty-seven participants were randomized and 65 were included in the modified intention-to-treat analysis: 16 received NR, 15 NMN, 17 nicotinamide, and 17 placebo.

How large was the Berven crossover comparison?

Stage 1 compared NR and NMN in six healthy adults, three women and three men, using an open-label crossover design. Its small sample makes the result exploratory.

Did NMN or NR raise brain NAD+ after eight days?

Not detectably at the group level in the six-person crossover. The same paper later studied four weeks of NR only and found a significant pooled brain NAD+ increase across six healthy adults and six people with Parkinson’s disease.

Does the brain result prove that NR is better than NMN for the brain?

No. NMN was not tested in the four-week stage, and the eight-day head-to-head comparison found no significant brain difference. The study measured a biomarker, not cognition or clinical benefit.

What did the study find about nicotinamide or Nam?

In the Nature Metabolism trial, 500 mg per day of nicotinamide did not produce a significant chronic whole-blood NAD+ increase. It caused an acute, more-than-eightfold median increase in homocysteine iAUC, a biomarker finding rather than a clinical-outcome result.

Why do molecular weights matter when comparing equal gram amounts?

Equal masses do not contain equal numbers of molecules. The crossover paper used NR chloride at 290.70 g/mol and NMN at 334.22 g/mol; it reported that the NR difference remained significant after adjusting for this approximately 15% molar difference.

What is the NAD+ salvage pathway?

It is a recycling network that converts vitamin B3-related molecules into NAD+. NR can enter through nicotinamide riboside kinases to form NMN, while NMNAT enzymes convert NMN to NAD+.

What role might the gut microbiome play?

The Nature Metabolism paper proposed, from human biomarker data plus ex vivo fermentation, that microbial conversion to nicotinic acid may contribute to the sustained blood NAD+ response. The ex vivo findings are mechanistic evidence, not proof of a health benefit.

Does WebberScience sell NMN or NR?

The current WebberScience catalog does not list NMN or NR. It lists NAD+ 500mg laboratory material, which is a different material and must not be treated as interchangeable with the oral precursors used in the cited studies.

Sources

• Christen S, et al. “The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans.” Nature Metabolism. 2026;8:62–73. PMID 41540253.
• Nature Metabolism full article and source-data links. DOI 10.1038/s42255-025-01421-8.
• Berven H, et al. “The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation.” iScience. 2026;29:114764. PMID 41858901.
• Europe PMC full-text record for the Berven study. PMCID PMC12996706.

Continue NAD+ Research at WebberScience

Browse the WebberScience NAD+ research category or review NAD+ 500mg laboratory material. The catalog material is NAD+, not NMN or NR, and the 500mg vial label identifies quantity only. It is not a dose, research amount, route, administration instruction, or evidence of equivalence to the oral precursors in these studies.

Research disclaimer: For research and laboratory use only. Not intended for human or veterinary use. This article does not constitute medical advice. WebberScience does not provide dosing, route, administration, treatment, efficacy, longevity, or safety guidance.